openPR Logo
Press release

Deadline Expires This Year for Fen-Phen Class Action Members

07-27-2011 09:16 AM CET | Politics, Law & Society

Press release from: Petroff & Associates

Deadline Expires This Year for Fen-Phen Class Action Members’
Heart Disease Diagnosis or Surgery

DALLAS, TX — July 2011 —Petroff & Associates is trying to alert all members of the fen-phen class action settlement that their legal right to qualify for additional compensation is likely coming to a close by the end of this year, if not sooner.

Members of the fen-phen class action settlement can file for “progression benefits” if they experience one of the following situations before his/her individual deadline expires this year:
• Heart valve surgery
• Recommended heart valve surgery by a doctor, but surgery cannot be performed due to medical conditions
• Heart failure, heart arrhythmias, stroke or pulmonary hypertension that results in a person’s demise
• Residual problems caused by a stroke, lasting for a period of at least six months
• Blood clot causing kidney damage with dialysis, abdominal surgery or amputation of an arm or a leg
• Heart transplant
• Ventricular fibrillation or ventricular tachycardia
• Endocardial fibrosis
• Coma due to cardiac arrest
• Complications or worsening of the heart, lung or valve conditions following a valve surgery

Which class members are eligible for compensation?

There are three categories of class members within the class action settlement who are eligible to qualify for progression benefits and additional compensation:
• Surgery/ill patients - those who need heart valve surgery or have had valve surgery, or experienced any of the above conditions after taking fen-phen
• Surgery candidates - those who are candidates for valve surgery but may not know it
• Family - relatives/heirs of fen-phen victims who have died

How to file a claim?
First, individuals must determine if they – or a family member who has died – are included in the “Nationwide Class Action Settlement Agreement with American Home Products” and have a personal “Diet Drug Recipient Number.” Individuals may contact the Trust at 1-800-481-7947 or http://www.7thamendmentdietdrugs.com.

Class members must have registered with the AHP Settlement Trust by filing a "Blue" Form or a "Green" Form on or before May 3, 2003. Anyone who filed the necessary paperwork before the deadline in 2003 has the right to try to prove that they meet the criteria for additional compensation.

Second, they must determine whether they qualify for progression benefits. There is a questionnaire and additional information on the Petroff & Associates’ website that will help individuals determine whether they may qualify for progression benefits and a cash settlement.

Filing a claim is a complicated and confusing process. To file a claim, qualified class members must prove they took fen-phen and had an echocardiogram by the end of the screening period, Jan. 3, 2003, that showed at least mild leakage from the mitral or aortic heart valve.

While fen-phen class members must experience a qualifying event before the 2011 deadline to be eligible for a cash settlement, they can file a claim the later of November 8, 2014, or four years after the qualifying medical event occurs.

About Petroff & Associates
The law firm of Petroff & Associates is one of the most experienced law firms in the country regarding fen-phen litigation. Since 1997, the law firm has represented thousands of people nationwide against American Home Products Corp. for various types of injuries associated with the weight loss drugs fen-phen, Pondimin and Redux. The firm was founded and is led by Kip Petroff, who has written a book recounting his personal experiences with the on-going fen-phen litigation. Battling Goliath: Inside a $22 Billion Legal Scandal will be available fall 2011. Follow “Fen-Phen Deadline 2011” on Facebook at facebook.com/#!/fenphen2011 and on Twitter at twitter.com/#!/fenphen2011. For more information or to contact an attorney at Petroff & Associates, please visit petroffassociates.com.

# # #

This alert is for informational purposes only and is not intended to be legal advice. Transmission is not intended to create and receipt does not establish an attorney-client relationship. For legal advice, consult an attorney. For more information about Petroff & Associates and our practice, please visit petroffassociates.com.

Petroff & Associates
3838 Oak Lawn Ave.
Suite 1620
Dallas, Texas 75219
(214) 526-5300

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deadline Expires This Year for Fen-Phen Class Action Members here

News-ID: 185085 • Views:

More Releases for Heart

Heart disease and Heart Attacks - Kaffailham.gr
Καρδιολόγος Αθηνα - https://kaffailham.gr When people talk about heart disease or heart attacks. The arteries that they are talking about are the arteries that actually provide blood to the heart. Remember the heart itself is a muscle. It itself needs oxygen. So you have these arteries right over here, the red tubes. Those are arteries. and then the blue ones are veins. They're taking the de-oxygenated blood away from the tissue
Artificial Heart Implant Market May See a Big Move | Major Giants Jarvik Heart, …
The Latest survey report on Artificial Heart Implant Market sheds lights on changing dynamics of each of the subsegments of Industry. As the shift to value continues, Artificial Heart Implant organizations have the dual challenge of increasing interoperability to improve clinical performance and the patient experience. Some of the companies listed in the study from complete survey list are Medtronic, Boston Scientific, Abbott, Terumo, B.Braun, SynCardia, BiVACOR, CARMAT, ReinHeart TAH
Heart Pump Device Market - Potential Innovations 2025 | Terumo, Jarvik Heart
Heart Pump Device Market: Snapshot Heart pump devices are essentially mechanical pumps playing the role of ventricular assist devices. These are surgically implanted and are used for temporarily supporting the functions of heart in people with weak heart or irregular blood flow. These devices are notably used as a bridge to cardiac transplantation for patients suffering with end stage heart failure. They can also be used in patients during and after
Congestive Heart Failure (Heart Failure)-Pipeline Review, H2 2017
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Congestive Heart Failure (Heart Failure)-Pipeline Review, H2 2017, provides an overview of the Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline landscape. Heart failure is also known as congestive heart failure (CHF). CHF is a condition in which the heart is no longer able to pump out enough oxygen-rich blood. Symptoms include cough, fatigue, weakness, faintness, loss of appetite, swollen (enlarged) liver
Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2017, provides an overview of the Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline landscape. Heart failure is also known as congestive heart failure (CHF).
Congestive Heart Failure (Heart Failure) Market Research Report
Latest industry research report on: Congestive Heart Failure (Heart Failure) Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts GlobalData's clinical trial report, Congestive Heart Failure (Heart Failure) Global Clinical Trials Review, H1, 2017" provides an overview of Congestive Heart Failure (Heart Failure) clinical trials scenario. This report provides top line data relating to the clinical trials on Congestive Heart Failure (Heart Failure). Report includes an